Journal of Neurorestoratology
Volume 9

Number 4

Article 8

2021

Silencing myelin protein zero-like 1 expression suppresses cell
proliferation and invasiveness of human glioma cells by inhibiting
multiple cancer-associated signal pathways
Simiao Zhang
Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014,
Henan, China

Sandian Zhang
Department of Radiation Oncology, Li Huili Hospital of Ningbo Medical Center, Ningbo 315040, Zhejiang,
China

Hongzhen Wang
Department of Orthopaedics, the First People's Hospital of Kunshan City, Kunshan 215300, Jiangsu, China

Xuege Huang
Department of Cell Biology, School of Medicine, Soochow University, Suzhou 215123, Jiangsu, China

Jinzhi Wang
Department
of Cell
Biology,works
School
Medicine, Soochow University, Suzhou 215123, Jiangsu, China
Follow this and
additional
at:of
https://dc.tsinghuajournals.com/journal-of-neurorestoratology
Part of the Neuroscience and Neurobiology Commons
See next page for additional authors

Recommended Citation
Zhang, Simiao; Zhang, Sandian; Wang, Hongzhen; Huang, Xuege; Wang, Jinzhi; Li, Jingna; Cheng, Dan;
Wang, Hongwei; Lu, Daru; and Wang, Yunliang (2021) "Silencing myelin protein zero-like 1 expression
suppresses cell proliferation and invasiveness of human glioma cells by inhibiting multiple cancerassociated signal pathways," Journal of Neurorestoratology: Vol. 9: No. 4, Article 8.
DOI: https://doi.org/10.26599/JNR.2021.9040017
Available at: https://dc.tsinghuajournals.com/journal-of-neurorestoratology/vol9/iss4/8

This Research Article is brought to you for free and open access by Tsinghua University Press: Journals Publishing.
It has been accepted for inclusion in Journal of Neurorestoratology by an authorized editor of Tsinghua University
Press: Journals Publishing.

Silencing myelin protein zero-like 1 expression suppresses cell proliferation and
invasiveness of human glioma cells by inhibiting multiple cancer-associated
signal pathways
Authors
Simiao Zhang, Sandian Zhang, Hongzhen Wang, Xuege Huang, Jinzhi Wang, Jingna Li, Dan Cheng,
Hongwei Wang, Daru Lu, and Yunliang Wang

This research article is available in Journal of Neurorestoratology: https://dc.tsinghuajournals.com/journal-ofneurorestoratology/vol9/iss4/8

Journal of Neurorestoratology
DOI 10.26599/JNR.2021.9040017

2021, 9(4): 229–244
ISSN 2324-2426

RESEARCH ARTICLE

Silencing myelin protein zero-like 1 expression suppresses cell
proliferation and invasiveness of human glioma cells by inhibiting
multiple cancer-associated signal pathways
Simiao Zhang1,§, Sandian Zhang2,§, Hongzhen Wang3,§, Xuege Huang4, Jinzhi Wang4, Jingna Li1, Dan Cheng1,
Hongwei Wang5, Daru Lu6,7 (), Yunliang Wang1,8 ()
Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, Henan, China
Department of Radiation Oncology, Li Huili Hospital of Ningbo Medical Center, Ningbo 315040, Zhejiang, China
3 Department of Orthopaedics, the First People's Hospital of Kunshan City, Kunshan 215300, Jiangsu, China
4 Department of Cell Biology, School of Medicine, Soochow University, Suzhou 215123, Jiangsu, China
5 Shanghai Realgen Biotech Inc., Pudong New District, Shanghai 203215, China
6 State Key Laboratory of Genetic Engineering and MOE Engineering Research Center of Gene Technology, School of Life Sciences,
Fudan University, Shanghai 200032, China
7 NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Key Laboratory of Birth Defects and Reproductive Health,
Chongqing Population and Family Planning, Science and Technology Research Institute, Chongqing 400020 ,China
8 Department of Neurology, The 960 Central Hospital of PLA, Zibo 255300, Shangdong, China
§
These authors contributed equally to this work.
1
2

ARTICLE INFO

ABSTRACT

Received: 27 June, 2021
Revised: 29 July, 2021
Accepted: 16 August, 2021

Glioma is the most common primary malignant tumor of the adult
central nervous system. It has high morbidity and poor survival. Myelin
protein zero-like protein 1 (MPZL1) is a cell surface glycoprotein that
activates numerous adhesion-dependent signaling pathways. MPZL1
plays important roles in human cancers that include metastatic process;
however, it is not clear if MPZL1 plays a role in human glioma. Therefore,
this study aimed to determine if silencing MPZL1 impacted the cell
proliferative features of human glioma cells. First, MPZL1 expression
was investigated in human glioma samples and tumor cell lines. Then
the effects of small interfering RNA (siRNA)-targeting MPZL1 were
analyzed on proliferation, colony formation, cell cycle progression, and
invasion of human glioma cells. The results from this study demonstrated
that MPZL1 was highly expressed in human glioma tissues and glioma
cell lines. In addition, knockdown of MPZL1 significantly inhibited cell
proliferation, colony formation, and invasiveness of glioma cells, and
effectively induced cell cycle arrest at the G1 phase. Western blotting
analysis indicated that silencing MPZL1 expression downregulated the
expression of matrix metalloproteinase-2 (MMP-2), WNT1, caspase-3,
cyclin A1, epidermal growth factor receptor (EGFR), and signal
transducer and activator of transcription 3 (STAT3), and upregulated
p53. The results from this study suggest that MPZL1 might be a marker
for tumors and could be a potential therapeutic target for human glioma.
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1

Introduction

Glioma is the most common primary malignant
intracranial tumor of the central nervous system
in adults and is characterized by high morbidity
and poor survival [1, 2]. Glioma regulates cell
shape and volume by changing the membrane
potential [3, 4], producing a variety of secretory
proteases that dissolve the extracellular matrix [5],
and proteins that increase the ability to migrate,
such as tenascin-C [6]; therefore, they migrate
through narrow extracellular spaces to achieve
diffuse infiltration. The boundary between tumor
and normal tissue can become unclear, which
causes challenges for surgery and radiotherapy.
In addition, it is difficult for chemotherapeutics to
pass through the blood–brain barrier to exert their
expected therapeutic effects. Therefore, despite
the development of various treatments [7], the
efficacy and prognosis of patients with glioma
have not significantly changed. Glioma has a large
economic and psychological burden on patients.
In addition, it causes neurological deficits, such as
limb dysfunction. However, this function and the
patient’s quality of life can be improved through
nerve restoration therapy [8, 9].
Myelin protein zero-like 1 (MPZL1), which
is also known as PZR, belongs to a highly
phosphorylated transmembrane glycoprotein of
the immunoglobulin superfamily, which has a
high degree of homology with the extracellular
structure of myelin protein zero (myelin P0) [10].
The intracellular structure of MPZL1 protein
contains two immunosuppressive motifs (ITIMs)
with tyrosine phosphorylation sites. The Src
kinase in tyrosine protein kinases can catalyze
the phosphorylation of ITIMs. Phosphorylated
ITIMs can specifically bind to the Src homology 2
(SH2) domain of protein tyrosine phosphatase
SHP2 encoded by the protein tyrosine phosphatase
(PTP) non-receptor type II (PTPNII) gene, thereby
recruiting SHP2 [10]. MPZL1 is expressed in many

different types of tissues and is a highly conserved
protein, which strongly suggests that MPZL1
might play an important role in basic cell function
[11]. Studies have shown that MPZL1 plays a
role in the pathological process of many diseases,
which include liver cancer and ovarian cancer,
Src kinase mediates the overexpression of MPZL1;
therefore, inducing phosphorylation and activation
of cortin to degrade the extracellular matrix, and
enhance the migration and metastasis potential
of liver and ovarian cancer cells [12]. In human
EGFR-2 positive breast cancer, it forms a complex
with growth factor receptor-binding protein 2
adaptor and PTP nonreceptor type 11 to promote
the adhesion of breast cancer cells [13]. In addition,
MPZL1 gene expression and protein levels significantly increased in the tumor tissues from patients
with advanced gallbladder cancer. This study
hypothesized that the ITIMs of MPZL1 could
specifically bind to SHP2 (PTP-related factors
that promote tumors), and therefore, promoted
tumor cell proliferation and metastasis [14, 15].
Several studies mentioned previously confirmed that MPZL1 bound specifically to the SH2
domains of Src through its intracellular motifs,
which could cause activation of Src and play a role
in various tumors. Studies demonstrated that cell
infiltration of glioma in Src defective mice [16],
and Src played a role in malignant gliomas [17].
The specific inhibition of the in vitro and in vivo
growth of malignant gliomas after Src was
inhibited [18]. The signal transducer and activator
of transcription 3 contain the SH2 domain, and
signal transducer and activator of transcription 3
(STAT3) regulate the growth and self-renewal of
glioparamia tumor cells [19], silent STAT3 after
glue tumor cell infiltration, and tumor growth
inhibition [20], Src activates STAT3. Based on
the previous studies, MPZL1 could function by
influencing the signaling pathway of glioma;
however, few relevant studies are currently
available; therefore, this research will explore the
Journal of Neurorestoratology
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relationship between both.
In this study, if silencing MPZL1 impacted the
cell proliferative features of human glioma cells
was investigated. MPZL1 was highly expressed in
human glioma tissues and glioma cell lines. The
knockdown of MPZL1 significantly inhibited cell
proliferation, colony formation, and invasiveness
of glioma cells, and effectively induced cell cycle
arrest at the G1 phase. In addition, Western
blotting analysis revealed that silencing MPZL1
expression downregulated the expression of
matrix metalloproteinase-2 (MMP-2), WNT1,
caspase-3, cyclin A1, epidermal growth factor
receptor (EGFR), and STAT3, and upregulating
p53. Therefore, the results from our study suggest
that MPZL1 might be a tumor marker and could
be a potential therapeutic target for human glioma.

2 Materials and methods
2.1

Chemicals and antibodies

Mouse antihuman MPZL1 polyclonal antibody
was purchased from ProteinTech Group (Abcam,
Cambridge, MA, USA). Mouse antihuman
polyclonal antibodies against MMP-2, WNT1,
caspase-3, cyclin A1, EGFR, p53, and STAT3 were
purchased from ImmunoWay Biotechnology
Company (Plano, TX, USA). Lipofectamine 2000
and TRIzol were obtained from Invitrogen
Corporation (Carlsbad, CA, USA). Murine
Leukemia Virus (M-MLV) reverse transcriptase
was purchased from Fermentas (Waltham, MA,
USA).
2.2

Cell culture

The U251 and U87 human malignant glioma cell
lines were purchased from the Shanghai Institutes
for Biological Sciences of the Chinese Academy of
Sciences (Shanghai, China). Both cell lines were
authenticated in 2019 using the short tandem
repeat method. Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Hyclone, USA)
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that contained 10% fetal bovine serum (FBS) at
37 ˚C in a humidified incubator with 5% CO2. Cell
culture media and FBS were purchased from
Gibco BRL (Grand Island, NY, USA).
2.3

Glioma sample collection

In total, 26 formalin-fixed, paraffin-embedded
tissues that were obtained from human glioma
from patients at the 960 Central Hospital of PLA
were included in the study. All cases were confirmed by clinical and pathological analysis. The
experimental protocols for the present study were
approved by the hospital ethics committee.
2.4

Immunohistochemistry

Paraffin-embedded tissue blocks were sectioned
and stained for MPZL1 with an anti-MPZL1
antibody. In summary, the sections were
deparaffinized in xylene, rehydrated through a
series of graded alcohol. Then, they were treated
with methanol that contained 3% hydrogen
peroxide for 10 min to block endogenous
peroxidase activity. Sections were immersed in
10 mmol/L citrate buffer (pH 6.0) in a pressure
cooker at 120 ˚C for 20 min for antigen retrieval.
Then, nonspecific antibody binding was blocked
by incubation in 10% normal goat serum (HRP,
Hangzhou, China ) at room temperature for 30 min.
Then, the sections were incubated with a polyclonal
antibody against MPZL1 (diluted 1:400) at 4 ˚C in
for 1 h in a moist chamber. Following five washes
in phosphate buffer saline (PBS) with 0.05% Tween
20, sections were incubated with 10% horseradish
peroxidase-conjugated goat anti-rabbit IgG
secondary antibody (HRP, Hangzhou, China)
for 30 min at room temperature. Visualization
was performed using 3,3-diaminobenzidinetetrahydrochloride-dihydrate (DAB) (Phygene,
Wuhan, China) and counter-stained with
hematoxylin. Then, sections were dehydrated,
mounted, and analyzed using standard light
microscopy with high power magnification (× 400).
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2.5 Recombination lentivirus generation and
cell infection
The human MPZL1 (Gen-Bank accession No. NM_
024569) specific small interfering RNA (siRNA)
sequence was designed using online siRNA tools
that were provided by Invitrogen (CA, USA):
5′-TCTGCTCATCAGCATGATT-3′. The negative
control sequence (5′-TTCTCCGAACGTGTCACGT3′) chosen in this study was used as a scrambled
control [21]. Oligonucleotides that contained
sense and antisense sequences were synthesized
and subcloned into the lentivirus-based vector
GV115 using enzymes Age I and EcoR I. The
resulting lentiviral vectors were used to generate
lentiviruses in HEK293T cells by cotransfection
of the recombinant GV115 vectors, pHelper 1.0,
and pHelper 2.0 plasmids using Lipofectamine
2000. The viral particles were collected from
the medium 48–72 h after transfection and
concentrated using ultracentrifugation, which
yielded Lv-si-MPZL1 and Lv-si-CTRL retroviral
supernatants. Viral titers were determined by
serial dilutions by counting the number of infected
green cells under a fluorescence microscope
following HEK293T cell infection. There were
two experimental groups for or each cell line:
the MPZL1-siRNA group (cells infected with
Lv-si-MPZL1), and the scrambled siRNA (scrsiRNA) group (cells infected with Lv-si-CTRL)
for cell infection. The U251 and U87 cells were
subcultured into six-well culture plates at 70%–
80% confluence and infected with both previously
mentioned lentiviruses at a multiplicity of
infection of 20.
2.6 RNA extraction, reverse transcription, and
quantitative PCR
Total RNA was extracted from cultured glioma
cells using TRIzol Reagent. The synthesis of
cDNA was performed by using Moloney murine
leukemia virus reverse transcriptase (M-MLV-RT;
Promega, USA) according to the manufacturer’s
instructions. The quantitative real-time PCR

(qRT-PCR) analysis was performed using the
SYBR Green One-Step qRT-PCR Kit (Invitrogen,
CA, USA) and SYBR green I to detect the mRNA
levels of MPZL1, with glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as an internal control.
The following primers were used: forward
5′-ACGCCAAAAGAAATCTTCGTGG-3′ and reverse 5′-TCAACCCGCCAGTCGTACTA-3′ for MPZL1
(85 bp), forward 5′-TGACTTCAACAGCGAACCCA-3′
and reverse 5′-CACCCTGTTGCTGTAGCCAAA-3′
for GAPDH (121 bp). Relative gene expression
was determined using the 2−ΔΔCT algorithm. The
experiments were performed three times.
2.7

Cellomics arrayscan assay

In summary, U251 cells that were infected with
lentivirus-mediated MPZL1-siRNA or scr-siRNA
were seeded into 96-well microplates at 2 × 103
cells/well and incubated at 37 ˚C in a humidified
atmosphere that contained 5% CO2. The infected
U251 cells were imaged with green fluorescence
and counted using the Cellomics ArrayScan highcontent screening platform once a day for 5 days.
Each experiment was performed at least three
times. The collected data were analyzed to establish
the 5-day growth curve.
2.8

Methyl thiazolyl tetrazolium assay

In summary, lentivirus infected glioma cells that
were obtained from different groups (MPZL1siRNA group, scr-siRNA group) were seeded
into 96-well plates at 2 × 103 cells/well. At the
time points following incubation (1, 2, 3, 4, and
5 days), methyl thiazolyl tetrazolium (MTT)
solution was added to each well at 5 mg/mL
and incubated at 37 ˚C for 4 h. Then, 100 μL of
dimethyl sulfoxide was added to each well after
the entire supernatant had been removed from
the wells. The absorbance at 570 nm of each
well was determined with an enzyme-linked
immunosorbent assay reader (Tecan infinite
200, Tecan) at 595 nm. The experiments were
repeated three times.
Journal of Neurorestoratology
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2.9

Colony formation assay

After 5 days of lentivirus treatment with control
siRNA expressing lentivirus (scr-siRNA group)
or MPZL1 targeted siRNA expressing lentivirus
(MPZL1-siRNA group), lentivirus infected human
glioma cells were trypsinized, counted, and seeded
into six-well plates at 3 × 103 cells/well. The
medium was refreshed at 2-day intervals. After
14 days of culturing in a 5% CO2 incubator at 37 ˚C,
the cells were fixed with 4% paraformaldehyde
for 30 min at room temperature and stained with
freshly prepared Giemsa solution for 20 min.
Then, they were washed thoroughly with water,
and air dried. The stained colonies were observed
and analyzed using an Olympus (Tokyo, Japan)
inverted microscope.
2.10

Flow cytometry analysis

Cell cycle progression was determined by
propidium iodide (PI) staining using a flow
cytometer (FACS Calibur, BD Biosciences). In
summary, 5 days after infection, the cells in each
well were harvested at 80% confluence, followed
by fixing with 70% (v/v) cold ethanol and incubated
for 30 min at 4 ˚C. After centrifugation, the ethanol
was discarded, and cells were resuspended in
PI/RNase/PBS (100 μg/mL PI and 10 μg/mL
DNase-free RNase A solution), and incubated
in dark for 30 min at room temperature. The
suspension was filtered through a 50-μm nylon
mesh, and DNA quantities from different cell
cycles phases (G0/G1, S, and G2/M) were analyzed
by using FACS Calibur flow cytometer.
2.11

In vitro cell invasion assay

In vitro cell invasion assays were performed using
transwell chamber inserts (8.0-μm pore size;
Costar, Cambridge, NY, USA) with Matrigel (BD
Biosciences, San Jose, CA, USA) according to
the manufacturer’s protocol. In summary, the
transfected cells were trypsinized, resuspended,
and seeded into the upper compartment of the
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chamber at 2 × 105 cells in serum-free DMEM.
The lower chamber was filled with 0.5 mL of
DMEM supplemented with 30% FCS that acted
as the source of chemoattractant. Following 48 h
incubation, cells on the top surface of the insert
were removed by scraping the surface with a
cotton swab, and the cells that had migrated
through the permeable membrane were fixed with
4% paraformaldehyde and stained with Giemsa.
Photographs of five randomly chosen fields of the
fixed cells (at 200 × magnification) were taken and
counted using a microscope (Olympus, Tokyo,
Japan). Each assay was carried out in triplicate.
2.12

Western blotting analysis

After lentiviral infection for 5 days, human glioma
cells from each group were collected, washed with
ice-cold PBS, and lysed in lysis buffer (150 mM
NaCl, 50 mM Tris-HCl, pH 7.4, 2 mM EDTA, and
1% NP-40) that contained protease inhibitors. Clear
protein extracts were obtained by centrifugation,
and total cellular protein concentration was
measured using the bicinchoninic acid assay
according to the manufacturer’s protocol (Pierce,
USA). Equal amounts of protein lysates (50 μg)
were resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to polyvinylidene difluoride
(PVDF) membranes. Nonspecific binding sites
on the membranes were blocked with 5% nonfat
milk in Tris-buffered saline with 0.05% Tween
20 for 1 h at 4 ˚C. Then, the membranes were
incubated at 4 ˚C with specific antibodies to
MPZL1, MMP-2, WNT1, caspase-3, cyclin A1,
EGFR, p53, STAT3, GAPDH, or β-actin. The
membranes were incubated with peroxidaseconjugated secondary antibodies at 1:5000 dilution
at room temperature for 1 h. Protein detection and
visualization were performed using an enhanced
chemiluminescence kit (Amersham Biosciences)
on X-ray film. The GAPDH and β-actin were used
as loading controls.
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2.13

Statistical analysis

Data were presented as the mean ± standard
deviation of ≥ 3 independent experiments.
Differences between groups were assessed using
a Student’s t-test and p < 0.05 was defined as a
significant difference. Statistical analysis was
performed with GraphPad Prism 6 (GraphPad
Software, San Diego, USA).

3

Results

3.1 MPZL1 is overexpressed in human glioma
samples
In total, 26 cases were identified as glioblastoma

after pathological examination, of which two
cases were screened out due to tissue rupture
and contamination, the remaining 24 cases
were qualified specimens. Of the 24 patients, 21
(87.50%) were classified as positive for expression
of MPZL1. MPZL1 protein with positive staining
was shown in the nuclei and cytoplasm of human
glioma tissues [Fig. 1(A), panel a], and MPZL1
staining was not detected in normal brain tissues
[Fig. 1(A), panel b]. The expression of MPZL1 in
human glioma tissues was higher than that in
normal brain tissues. To determine the MPZL1
expression in different types of glioma cells, the
qRT-PCR assay was performed. As shown in

Fig. 1 Analysis for expression of MPZL1 and lentivirus infection. (A) Immunohistochemistry results showing the expression
of MPZL1 protein in human glioma (a) and normal (b) tissue (× 400). (B) qRT-PCR analysis for MPZL1 mRNA levels in
human glioma cells. (C) Fluorescence image of lentivirus infection. The cellular imaging experiments demonstrate showed
the successful delivery of siRNA into U251 and U87 cells (× 400), respectively; (D) MPZL1 mRNA expression levels of
MPZL1-silenced and nonsilenced cells detected by qRT-PCR; (E) MPZL1 protein expression levels of MPZL1 silenced and
nonsilenced U251 and U87 cells detected by Western blot. * p < 0.05, ** p < 0.01, comparison with the scr-siRNA group.
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Fig. 1(B), MPZL1 mRNA expression significantly
increased in the 4 human glioma cell lines,
U87, U373, A172, and U251. Therefore, these
results demonstrated that MPZL1 expression was
significantly elevated in human glioma tumors
and glioma cells.
3.2 Lentivirus-mediated RNAi efficiently blocks
MPZL1 expression in human glioma cells
A lentivirus-mediated siRNA targeting MPZL1
vector (MPZL1-siRNA) and scr-siRNA vector were
constructed. In the transfection experiment, > 90%
of the cells showed green fluorescence, which
indicated that the tumor cells were successfully
infected [Fig. 1(C)]. To determine the efficiency of
silencing, qRT-PCR and Western blot analysis was
performed to determine the mRNA and protein
expression levels of MPZL1, respectively. The
results showed that the expression levels of
MPZL1 mRNA [Fig. 1(D)] and protein [Fig. 1(E)]
decreased in the MPZL1-siRNA group, compared
with that in the scr-siRNA group. These results
demonstrated that Lv-si-MPZL1 could silence the
expression of MPZL1 in human glioma cells.
3.3 Depletion of MPZL1 inhibits cell proliferation of human glioma cells
Cellomics ArrayScan assay was first used to
measure the effect of MPZL1-siRNA on cell
viability. Compared with that observed after
scr-siRNA treatment, the silencing of MPZL1
significantly inhibited the growth of U251 cells,
and the difference was more pronounced in a
time-dependent manner [p < 0.01; Fig. 2(A)]. The
MTT assay showed that the cell viability of U251
and U87 cells significantly decreased (p < 0.01),
compared with that of the scr-siRNA groups
[Fig. 2(B)].
In the colony formation assay, the numbers
of colonies that were formed by U251 cells in
the MPZL1-siRNA group (14.67 ± 1.53) were
significantly lower than that in the scr-siRNA
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group (110.00 ± 3.46; p < 0.01). In addition, the
number of colonies formed by U87 cells in the
MPZL1-siRNA group (1.33 ± 0.58) was significantly
lower than that in the scr-siRNA group [41.00 ±
3.00; p < 0.01; Fig. 2(C)]. These results suggest
that silencing MPZL1 with siRNA inhibited the
proliferation of human glioma cells in vitro.
3.4 MPZL1 knockdown inhibits invasiveness
of human glioma cells
In the transwell invasion assay, the number of
invaded U251 cells in the MPZL1-siRNA group
was 10.67 ± 0.58, which was significantly lower
than the scr-siRNA group [136.30 ± 1.53; p < 0.01;
Fig. 3(A)]. The number of invaded U87 cells was
21.33 ± 1.53 in the MPZL1-siRNA group and was
significantly lower than the scr-siRNA group
[91.67 ± 6.51; p < 0.01; Fig. 3(B)]. Therefore, these
results indicate that MPZL1 silencing suppressed
the invasiveness of human glioma cells.
3.5 Silencing MPZL1 inhibits the cell cycle
progression of human glioma cells
The cell processes were analyzed by flow
cytometry to understand the potential mechanism
of RNAi-mediated cell growth inhibition. As
shown in Fig. 4(A) (panel a and b), compared with
the scr-siRNA group, silencing MPZL1 resulted
in an increased percentage of U251 cells in the G0/
G1 phase (46.00% ± 0.70% versus 56.22% ± 0.31%,
p < 0.01). In addition, the percentage of S phase
cells decreased significantly (36.51% ± 0.26% versus
25.89% ± 0.35%, p < 0.01), and the percentage of
phase G2/M cells had no statistical significance
(17.49% ± 0.49% versus 17.90% ± 0.41%, p > 0.05).
Similarly, silencing MPZL1 resulted in an
increased percentage of U87 cells in the G0/G1
phase (52.16% ± 0.10% versus 58.63% ± 1.17%,
p < 0.01), concomitantly with a significant decrease
in the percentage of cells in the S phase (29.66% ±
0.27% versus 24.75% ± 0.88%, p < 0.01), and no
significant changes in the percentage of cells in
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Fig. 2 Effects of MPZL1 silencing on the proliferation of human glioma cells. (A) Cellomics ArrayScan assay. The results
showed that MPZL1-siRNA depressed the growth of U251 cells as compared with the scr-siRNA with a time-dependent
relationship. (B) MTT assay. Cell proliferation was analyzed by the MTT assay in MPZL1-silenced and nonsilenced cells.
MPZL1-siRNA repressed the growth curves of U251 and U87 cells compared with the scr-siRNA group; and (C) colony
formation assay. The results showed that MPZL1-siRNA decreased the clone numbers of U251 and U87 cells compared
with the scr-siRNA group. * p < 0.05, ** p < 0.01, comparison with the scr-siRNA group.

the G2/M phase were observed (18.19% ± 0.31%
versus 16.61% ± 2.04%, p > 0.05). Collectively,
these results demonstrated that the knockdown
of MPZL1 expression suppressed cell cycle progression in U251 and U87 cells.
3.6 Silencing MPZL1 impacts the expression of
multiple cancer-associated signaling pathways
To investigate the possible molecular mechanisms
that underlie the inhibition of cell functions after

MPZL1 knockdown, the expression of multiple
cancer-associated signaling pathways was
analyzed. Silencing MPZL1 downregulated the
expression of MMP-2, WNT1, caspase-3, cyclin A1,
EGFR, and STAT3, and upregulated the expression
of p53 in U251 cells [Fig. 4(B)]. Therefore, these
results suggest that silencing MPZL1 might
inhibit cell proliferation and the invasiveness of
glioma cells by regulating these cancer-associated
signaling pathways.
Journal of Neurorestoratology
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Fig. 3 Effects of MPZL1 silencing on the invasion of human glioma cells. (A) Effects of MPZL1-siRNA on the invasion of
human glioma cells. Matrigel invasion assays of U251 cells were performed and the quantified data are shown in the
diagram. (B) Effects of MPZL1-siRNA on the invasion of human glioma cells. Matrigel invasion assays of U87 cells were
performed, and the quantified data are shown in the diagram. Inhibition of MPZL1 decreased human glioma cell invasion.
* p < 0.05, ** p < 0.01, compared with the scr-siRNA group cells.

Fig. 4 Analysis of flow cytometry and Western blotting. (A) Flow cytometry analysis of effects of MPZL1 on the cell cycle
distribution of human glioma cells. (a) Flow cytometry histogram and the number of cells under each phase of the cell cycle;
(b) numerical representation of the cells under each phase of the cell cycle. PI staining and flow cytometric analysis indicated
that the mechanism of cell growth inhibition of MPZL1 silencing on the human glioma cells was partly mediated via specific
cell cycle arrest. (B) Analysis of Western blot. MPZL1 silencing regulated the protein levels of related molecules in U251 cells,
including MMP-2, WNT1, caspase-3, cyclin A1, EGFR, p53, and STAT3. * p < 0.05, ** p < 0.01, compared with the scr-siRNA group.
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4 Discussion
The intracellular motif of MPZL1 specifically
binds to the SH2 domain of SHP2, and it promotes
cell adhesion by recruiting and activating SHP2,
which was confirmed in previous studies into
gallbladder cancer [14, 15, 22]. The SHP2 regulates
the proliferation, differentiation, and survival of
tumor cells through WNT/β-catenin, januskinase
(JAK)/STAT and other pathways, and is a tumorpromoting protein [23–25]. Increasing evidence
confirmed that MPZL1 contributes to the progression and metastasis of human tumors [12, 15].
However, the role of this protein in human
glioma is unclear. In this study, MPZL1 was highly
expressed in the human glioma tissues and cell
lines, which indicated that MPZL1 might play
an important role in the development of human
glioma.
First, it was confirmed by immunohistochemical
analysis that MPZL1 was highly expressed in
glioma tumor tissues, and then the effect of MPZL1
on the pathogenesis of glioma was studied in
vitro using glioma cell lines. Second, the qRTPCR analysis demonstrated the universal high
expression of MPZL1 in glioma cells. Third, the
glioma cell line was transfected by constructing
lentiviral vectors of MPZL1-siRNA and scr-siRNA.
Finally, the viability, proliferation, and invasion
ability of the transfected tumor cell line were
tested, and compared with the scr-siRNA group,
the MPZL1-siRNA group was significantly
inhibited. In addition, the U251 and U87 cells that
were transfected with the MPZL1-siRNA group
stagnated at phase G0/G1, and the number
of phase S cells decreased significantly, which
demonstrated that their cell processes were
significantly inhibited. These findings suggest
that MPZL1 might be a target for human glioma
treatment.
To determine the mechanisms that underlie
the function of MPZL1 in human glioma, the
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expressions of several proteins that are associated
with tumor genesis and development were
examined, MPZL1 silencing downregulated the
expression of MMP-2, WNT1, caspase-3, cyclin A1,
EGFR, and STAT3, and upregulated the expression
of p53 in human glioma cells.
The WNT signaling pathway is divided into
β-catenin-dependence and independence. It
activates transcription programs, participates in
biological physiological and pathological processes,
and promotes cell proliferation, differentiation,
and homeostasis. When the WNT signal
component mutates, it activates the signaling
pathway and leads to the expression of specific
target genes that leads to tumorigenesis [26, 27].
WNT1 belongs to the WNT family and
participates in the classic WNT/β-catenin signal,
and upregulation in a variety of tumors [28, 29].
In addition, WNT1 induces secreted protein-1
to activate MMP, vascular endothelial growth
factor, and other proteins, and participates in
the regulation of tumor proliferation, invasion,
and metastasis [30]. The WNT/β-catenin
signaling pathway crosstalks with other signaling
pathways of glioma, such as EGFR/AKT, STAT3,
and notch, but its mechanism requires further
study [31].
MMP-2 is a member of the metalloproteinase
family, which degrades various components
of the extracellular matrix, changes the microenvironment of tumors, and facilitates tumor
cell migration [32, 33]. The migration of glioma
cells is special, and they actively migrate and this
is achieved in two ways: through the perivascular
space and the brain parenchyma. The vascular and
interstitial spaces contain a variety of extracellular
matrix molecules. To separate from the extracellular
matrix and promote the migration of tumor cells,
glioma cells secrete a large number of proteases,
which include MMP-2, to degrade the extracellular
matrix, reduce adhesion, and promote cell
migration [5].
Journal of Neurorestoratology
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Previous studies found that the expression of
MMP-2 in patients with glioma increased, which
was related to tumor invasion, angiogenesis,
metastasis, and the recurrence of glioma [34–36].
Caspase-3 is a key enzyme of apoptosis and a
key in apoptosis. Its active form plays a crucial
role in destroying cellular components related to
DNA repair and regulation [37–39]. Cyclin A1 is
a cell cycle regulator that participates in meiosis
and promotes proliferation [40].
The EGFR signaling network has crucial
roles in various cellular processes, including
cancer cell proliferation, migration, and survival.
EGFR is strongly implicated in the initiation
and progression of glioblastoma [41, 42]. The
p53 tumor-suppressor protein is a key factor
that maintains genetic stability by its multiple
regulatory roles on the cell cycle, apoptosis,
senescence, and differentiation [43–46].
STAT3 belongs to the STAT family of
transcription factors. Activation of STAT3 and its
target genes leads to many typical characteristics
of cancer, such as immune evasion, cell cycle
progression, antiapoptotic effects, proangiogenesis,
tumor invasion, and metastasis. STAT3 is
considered to be a viral oncogene because of its
ability to promote malignancy. STATS are activated
by many cytokines and inherent tyrosine kinase
activity [47–49], such as EGFR. In addition, tumor
protein Src is a STAT3 activator. MMP2 and MMP9
and other promoted growth factors proved to be
STAT3 target genes [50, 51]. In addition, STAT3
is constitutively activated in a variety of cancers,
which include glioblastoma, breast cancer, and
pancreatic cancer [52–54].
In our study, after the expression of MPZL1
was silenced, the expression of STAT3, STAT3
upstream activation factor EGFR and downstream target gene MMP2 lowered, which
proved that MPZL1 participated in the STAT3
signaling pathway. In addition, the expression
of WNT that crosstalks with STAT3 pathways
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were downregulated. Downregulation of these
proteins proves that MPZL1 plays a role in
glioma through multiple signaling pathways. In
summary, our results indicate that the capabilities
of MPZL1 to regulate cell proliferation and
invasion might be partly mediated by these
signaling proteins in human glioma cells. Further
experiments are required to understand its
molecular mechanism further.
In conclusion, RNAi-mediated downregulation
of MPZL1 expression inhibited the proliferation
and metastatic potential of human glioma cells
and regulated the expression of multiple cancerassociated signal pathways. However, the
molecular mechanism of MPZL1 is complex, and
further studies are required to understand the
correlation between the clinical aspects and
pathological findings.

5

Conclusion

The expression of MPZL1 in human glioma tumor
tissue is significantly higher than that in normal
brain tissue. The mechanism of MPZL1 promoting
the proliferation and invasion of glioma tumor
cells may be accomplished by adjusting the
expression of multiple proteins in multiple glioma
signaling pathways, such as STAT3 pathway and
WNT1 pathway. However, how MPZL1 affects
the protein expression in the signaling pathway
and the relationship between the pathways need
to be further studied.
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